AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22934858 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22934858 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 19900154 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 34
Study 19900154 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 34
Study 19900154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Exercise and Pravastatin
Number of subjects: 34
Study 19900154 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study 17609623 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 0
Study 17609623 — intervention group
Group type: COMPARATOR
Intervention: Episodic therapy
Number of subjects: 0
Study 10636271 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction (AMI)
Number of subjects: 1889
Study 10636271 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, systolic blood pressure, heart rate, and Killip class upon presentation
Number of subjects: 1889
Study 10636271 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system based on age and physical examination
Number of subjects: 1889
Study 8731641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate solution (Picolax)
Number of subjects: 59
Study 8731641 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol bowel lavage solution (Klean Prep)
Number of subjects: 59
Study 1413580 — intervention group
Group type: COMPARATOR
Intervention: Drugs only
Number of subjects: 126
Study 1413580 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs and graded walking
Number of subjects: 126
Study 1413580 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs and low-effort bicycle exercise
Number of subjects: 126
Study 4054193 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 4054193 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17
Study 4054193 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of original lipophilic beta-blocker
Number of subjects: 17
Study 30994855 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 114
Study 30994855 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 114
Study 30994855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 29322610 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 601
Study 29322610 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 601
Study 29322610 — intervention group
Group type: COMPARATOR
Intervention: additional OAD
Number of subjects: 601
Study 26795423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led proactive care intervention over 2 years
Number of subjects: 558
Study 26795423 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led proactive care intervention (10 sessions)
Number of subjects: 558
Study 26795423 — intervention group
Group type: COMPARATOR
Intervention: General practitioner (GP) treatment as usual
Number of subjects: 558
Study 24697877 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 24697877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24697877 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (during atorvastatin and placebo treatment)
Number of subjects: 0
Study 22332798 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (achieved glycemic control with HbA1c ≤ 8% for at least 2 months)
Number of subjects: 704
Study 20009090 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day rimonabant
Number of subjects: 368
Study 20009090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 18685543 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional spermicide
Number of subjects: 145
Study 18685543 — intervention group
Group type: COMPARATOR
Intervention: Control (condoms alone)
Number of subjects: 145
Study 15747005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-plating technique in Ni-Cr metal ceramic crown
Number of subjects: 64
Study 15747005 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64
Study 12795771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg IV
Number of subjects: 1002
Study 12795771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study 12795771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg IV (after second course)
Number of subjects: 1002
Study 10596705 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg b.i.d., for three weeks)
Number of subjects: 26
Study 10596705 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid medication (control group)
Number of subjects: 26
Study 8739860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy- and xylometazoline nasal sprays
Number of subjects: 0
Study 8739860 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vasoconstrictors
Number of subjects: 0
Study 8739860 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride in nasal decongestant solutions
Number of subjects: 0
Study 1924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg t.i.d.
Number of subjects: 93
Study 1924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg t.i.d.
Number of subjects: 93
Study 1924660 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 125 mg t.i.d.
Number of subjects: 93
Study 1924660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 29426270 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EvPO) 1000 mg, twice daily for 7 days
Number of subjects: 80
Study 29426270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 27005564 — intervention group
Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 120
Study 25450583 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg/day coQ10 capsules
Number of subjects: 44
Study 25450583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiglaucomatous therapy (various medications including metipranolol 0.3%, timolol 0.5%, dorzolamid, brinzolamid, brimonidine, bimatoprost, travoprost, and latanoprost)
Number of subjects: 0
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy and dual therapy (two substances in one drug)
Number of subjects: 0
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin agonists (PGA)
Number of subjects: 0
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol plus brinzolamide (combined therapy)
Number of subjects: 0
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol plus travoprost
Number of subjects: 0
Study 22189825 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 0
Study 22189825 — intervention group
Group type: COMPARATOR
Intervention: Not preserved eye drops (PGAs)
Number of subjects: 0
Study 20211296 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin, 100 mg/d
Number of subjects: 14466
Study 20211296 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 14466
Study 18551533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric or nasojejunal decompression
Number of subjects: 717
Study 18551533 — intervention group
Group type: COMPARATOR
Intervention: No decompression
Number of subjects: 717
Study 15629208 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 18
Study 15629208 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 12592333 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA --> CT
Number of subjects: 306
Study 12592333 — intervention group
Group type: COMPARATOR
Intervention: ATRA + CT
Number of subjects: 306
Study 10368815 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (5 g/day)
Number of subjects: 28
Study 10368815 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed (10 g/day)
Number of subjects: 28
Study 10368815 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g/day)
Number of subjects: 28
Study 8768018 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 24
Study 8768018 — intervention group
Group type: COMPARATOR
Intervention: Mixed parenteral and enteral nutrition
Number of subjects: 24
Study 1860749 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐1 (5 RM load, 3‐min rest periods, lower total work)
Number of subjects: 16
Study 1860749 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐2 (10 RM load, 1‐min rest periods, higher total work)
Number of subjects: 16
Study 1860749 — intervention group
Group type: COMPARATOR
Intervention: P‐1
Number of subjects: 16
Study 1860749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HREPs
Number of subjects: 16
Study 1860749 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐2
Number of subjects: 16
Study 7045615 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy alone
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy plus BCG
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus BCG
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher peripheral lymphocyte counts
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of positive delayed hypersensitivity skin tests
Number of subjects: 0
Study 7045615 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD conversion from negative to positive during therapy
Number of subjects: 0
Study 30870767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal TENS
Number of subjects: 24
Study 30870767 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation at 10 kHz
Number of subjects: 24
Study 30870767 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 29298599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational Enablement Protocol (VEP)
Number of subjects: 136
Study 29298599 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 136
Study 27090559 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted experience narratives (Study 2)
Number of subjects: 562
Study 27090559 — intervention group
Group type: EXPERIMENTAL
Intervention: Representative experience narratives (Study 1)
Number of subjects: 562
Study 27090559 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no narratives)
Number of subjects: 562
Study 24837306 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 40
Study 24837306 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 40
Study 22752889 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy < 12 hours
Number of subjects: 4478
Study 22752889 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy > 24 hours
Number of subjects: 4478
Study 19460609 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel administration before CABG
Number of subjects: 13819
Study 19460609 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel administration before CABG (Control)
Number of subjects: 13819
Study 17089420 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 80
Study 17089420 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Weight Loss Treatment (BWLT)
Number of subjects: 80
Study 16298489 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% w/v sucrose
Number of subjects: 242
Study 16298489 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 242
Study 12042269 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5/6 embryo transfer
Number of subjects: 0
Study 12042269 — intervention group
Group type: COMPARATOR
Intervention: Day 2 embryo transfer
Number of subjects: 0
Study 9797521 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TOE)
Number of subjects: 224
Study 8758833 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (30 min daily for 10 days at points PC6, LI4, ST36, RN4 and symptomatic points bilaterally)
Number of subjects: 40
Study 8758833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study 2523770 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure breathing at -12 cmH2O for 80 minutes
Number of subjects: 6
Study 2523770 — intervention group
Group type: COMPARATOR
Intervention: Control studies (identical conditions without negative pressure breathing)
Number of subjects: 6
Study 6985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazepam
Number of subjects: 57
Study 6985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6985 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exposure
Number of subjects: 57
Study 6985 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual exposure
Number of subjects: 57
Study 6985 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety evocation during treatment
Number of subjects: 57
Study 31295558 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BJ) after rinsing with water
Number of subjects: 10
Study 31295558 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BJ) after rinsing with antibacterial mouthwash
Number of subjects: 10
Study 31295558 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary test strips (Berkeley Test strips)
Number of subjects: 10
Study 31295558 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary sialin concentrations
Number of subjects: 10
Study 28586628 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises
Number of subjects: 143
Study 28586628 — intervention group
Group type: COMPARATOR
Intervention: Sham Radial Extracorporeal Shock Wave Therapy combined with supervised exercises
Number of subjects: 143
Study 28586628 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) in patients with calcification in rotator cuff
Number of subjects: 143
Study 26248619 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1879
Study 26248619 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1879
Study 26248619 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1879
Study 23923693 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded crutches
Number of subjects: 7
Study 23923693 — intervention group
Group type: COMPARATOR
Intervention: Standard crutches
Number of subjects: 7
Study 22011856 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean-treated group (12.95 g of soy protein for 90 days)
Number of subjects: 40
Study 19801931 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 148
Study 19801931 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 148
Study 16416230 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine (2.4 g/day; n = 9)
Number of subjects: 13
Study 16416230 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 4)
Number of subjects: 13
Study 15180141 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ketorolac tromethamine plus placebo
Number of subjects: 10
Study 15180141 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac tromethamine plus 1% prednisolone acetate
Number of subjects: 10
Study 11405194 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific dosage and duration not mentioned)
Number of subjects: 0
Study 9788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone (GHRH)
Number of subjects: 0
Study 9788006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 9788006 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (APO)
Number of subjects: 0
Study 8012861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (42 micrograms/nostril)
Number of subjects: 24
Study 8012861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (168 micrograms/nostril)
Number of subjects: 24
Study 8012861 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 24
Study 2557947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg plus ibuprofen 200 mg
Number of subjects: 58
Study 2557947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg alone
Number of subjects: 58
Study 2557947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 1195153 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 43
Study 1195153 — intervention group
Group type: COMPARATOR
Intervention: Will power
Number of subjects: 43
Study 1195153 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 43
Study 1195153 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (maintenance follow-up)
Number of subjects: 43
Study 29890366 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training for Depression (D-MCT)
Number of subjects: 0
Study 28124231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 138
Study 25893930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene 35 mg, selenium 55 µg, and green tea catechins 600 mg
Number of subjects: 60
Study 25893930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25893930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene, GTCs, and selenium supplementation
Number of subjects: 60
Study 24090777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exposure to antiepileptic drugs (AED)
Number of subjects: 1630
Study 24090777 — intervention group
Group type: EXPERIMENTAL
Intervention: No AED treatment during pregnancy
Number of subjects: 1630
Study 24090777 — intervention group
Group type: COMPARATOR
Intervention: No epilepsy (control group)
Number of subjects: 1630
Study 21470320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 45
Study 21470320 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 45
Study 21470320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18325646 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighting the unaffected leg during treadmill walking
Number of subjects: 10
Study 17140280 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg oral tablet
Number of subjects: 334
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 20 micrograms 2-hourly to a maximum of four doses (80 micrograms)
Number of subjects: 396
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 25 micrograms in the posterior fornix
Number of subjects: 396
Study 12830602 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone 1 mg inserted in the posterior fornix and repeated 6-hourly to a maximum of three doses
Number of subjects: 396
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (both oral and vaginal)
Number of subjects: 396
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 396
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 396
Study 12830602 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 396
Study 12830602 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 396
Study 10319823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 23
Study 10319823 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 23
Study 9125276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Patch (Dermestril 50, 4 mg E2, delivers 50 micrograms E2 daily)
Number of subjects: 32
Study 9125276 — intervention group
Group type: COMPARATOR
Intervention: Oral Tablet (2 mg micronized E2, daily administration)
Number of subjects: 32
Study 2103761 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 2103761 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 6769155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromoglycate (DSCG)
Number of subjects: 80
Study 6769155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31511682 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly generated experiments
Number of subjects: 548
Study 31511682 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning models trained on smaller randomized reaction dataset
Number of subjects: 548
Study 28697253 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to bupropion (n=511)
Number of subjects: 1522
Study 28697253 — intervention group
Group type: EXPERIMENTAL
Intervention: Augment current treatment with bupropion (n=506)
Number of subjects: 1522
Study 28697253 — intervention group
Group type: EXPERIMENTAL
Intervention: Augment with aripiprazole (n=505)
Number of subjects: 1522
Study 28697253 — intervention group
Group type: COMPARATOR
Intervention: Augment with bupropion (n=506)
Number of subjects: 1522
Study 25549192 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Expansion (HV)
Number of subjects: 20